Date | Price Target | Rating | Analyst |
---|---|---|---|
5/1/2024 | $26.00 | Buy | Craig Hallum |
12/29/2023 | $25.00 → $21.00 | Buy | BTIG Research |
8/21/2023 | $18.00 | Equal-Weight → Overweight | Stephens |
5/16/2023 | Outperform → Mkt Perform | Raymond James | |
5/9/2023 | $25.00 | Neutral → Buy | BTIG Research |
2/24/2023 | $20.00 | Hold → Buy | The Benchmark Company |
2/1/2023 | $15.00 | Hold → Buy | Needham |
8/26/2022 | Buy → Hold | The Benchmark Company |
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September 13-17 (booth #438). NeoGenomics' data offers key insights into circulating tumor DNA (ctDNA) analysis and next-generation sequencing (NGS), focusing on their role in early diagnosis and treatment optimization. "Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach," said Dr. Nathan Montgomery, Vice President of Medical Services at NeoGenomics. "Collectively, our findings demonstrate the potential
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will attend the Morgan Stanley 22nd Annual Global Healthcare Conference. Chris Smith, Chief Executive Officer, Jeff Sherman, Chief Financial Officer, and Warren Stone, Chief Commercial Officer, will participate in an in-person fireside chat on Friday, Sept. 6, 2024, at 10:45 a.m. ET in New York City. The presentation will be webcast live and accessible online via this link. A replay will be available on the Investor Relations section of the Company's website at ir.neogenomics.com. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the mo
Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 to $37 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024. Second Quarter 2024 Highlights As Compared To Second Quarter 2023 Consolidated revenue increased 12% to $165 million Clinical Services revenue increased 15% to $141 million Advanced Diagnostics revenue decreased 3% to $23 million Net loss decreased 23% to $19 million Adjusted EBITDA increased 630% to positive $11 million "The second quart
Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 to $37 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024. Second Quarter 2024 Highlights As Compared To Second Quarter 2023 Consolidated revenue increased 12% to $165 million Clinical Services revenue increased 15% to $141 million Advanced Diagnostics revenue decreased 3% to $23 million Net loss decreased 23% to $19 million Adjusted EBITDA increased 630% to positive $11 million "The second quart
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior
First Quarter Revenue Increased 14% to $156 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights Consolidated revenue increased 14% to $156 million Clinical Services revenue increased 17% to $135 million Advanced Diagnostics revenue decreased 3% to $22 million Net loss decreased 12% to $27 million Adjusted EBITDA was positive $3 million, an increase of 149% or $11 million "NeoGenomics had a strong start to 2024, with first quarter revenue growth of 14% yea
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
Craig Hallum resumed coverage of NeoGenomics with a rating of Buy and set a new price target of $26.00
BTIG Research reiterated coverage of NeoGenomics with a rating of Buy and set a new price target of $21.00 from $25.00 previously
Stephens upgraded NeoGenomics from Equal-Weight to Overweight and set a new price target of $18.00
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
10-Q - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
S-8 - NEOGENOMICS INC (0001077183) (Filer)
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year
FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.The Board has elected three new independent board members to join the board effective June 29, 2023. Elizabeth Floegel, Chief Information & Digital Officer of Numotion, a complex rehabilitation technology provider, will be a member of the Audit & Finance and Compliance Committees. Neil Gunn, former Chief Executive Officer of IDbyDNA, a developer of metagenomic technology for infectious disease testing and pathogen surveillance which was
FT. MYERS, FL / ACCESSWIRE / November 7, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, has appointed David B. Perez - a veteran leader in medical devices and health care services - to serve on its Board of Directors, effective November 3, 2022."I am thrilled to welcome David to our Board of Directors. With his proven record in growing and scaling highly-regulated companies, David brings valuable experience and insights to NeoGenomics as the company continues to expand its testing and information services to transform cancer care," said Lynn Tetrault, Chair of the Board of NeoGenomics.With 40 years of global executive lead
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).
The Q1 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, April 30, 2024 at 07:30 AM. Here's what investors need to know about the latest announcement. Earnings NeoGenomics beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05. Revenue was up $19.02 million from the same period last year. Analysis of Past Earnings Last quarter the company beat on EPS by $0.05 which was followed by a 12.0% increase in the share price the next day. Here's a look at NeoGenomics's past performance: Quarter Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 EPS Estimate -0.05 -0.02 -0.08 -0.11 -0.15 EPS Actual -0.02 0.03 0 -0.05 -0.09 Revenue Estimate 149.89M
BTIG analyst Mark Massaro maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $23 to $21.